Biopharma Dealmaking Should Accelerate In 2026, PwC Predicts

 
• By Joseph Haas
  
Forecast
PwC analysts expect an acceleration of biopharma dealmaking in 2026 • Source: Shutterstock

More from Deals

More from Business